Buspirone free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527931

CAS#: 36505-84-7 (free base)

Description: Buspirone is an anxiolytic psychotropic drug of the azapirone chemical class. It is primarily used to treat generalized anxiety disorder (GAD). Unlike most drugs predominantly used to treat anxiety, buspirone's pharmacology is not related to benzodiazepines or barbiturates, and so does not carry the risk of physical dependence and withdrawal symptoms for which those drug classes are known.


Chemical Structure

img
Buspirone free base
CAS# 36505-84-7 (free base)

Theoretical Analysis

MedKoo Cat#: 527931
Name: Buspirone free base
CAS#: 36505-84-7 (free base)
Chemical Formula: C21H31N5O2
Exact Mass: 385.25
Molecular Weight: 385.510
Elemental Analysis: C, 65.43; H, 8.11; N, 18.17; O, 8.30

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 36505-84-7 (free base)   33386-08-2 (HCl)    

Synonym: Buspirone free base, Buspirone, Buspar, MJ 9022 1, MJ-9022-1, MJ90221, MJ9022 1, MJ9022-1

IUPAC/Chemical Name: 8-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione

InChi Key: QWCRAEMEVRGPNT-UHFFFAOYSA-N

InChi Code: 1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2

SMILES Code: c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 385.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Torrisi SA, Salomone S, Geraci F, Caraci F, Bucolo C, Drago F, Leggio GM. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D(3) Receptor Blockade. Front Pharmacol. 2017 Oct 4;8:710. doi: 10.3389/fphar.2017.00710. eCollection 2017. PubMed PMID: 29046641; PubMed Central PMCID: PMC5632784.

2: Reynolds AR, Strickland JC, Stoops WW, Lile JA, Rush CR. Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine. Drug Alcohol Depend. 2017 Dec 1;181:25-29. doi: 10.1016/j.drugalcdep.2017.08.038. Epub 2017 Sep 22. PubMed PMID: 29028556; PubMed Central PMCID: PMC5683915.

3: Di Ciano P, Cormick PM, Stefan C, Wong E, Kim A, Remington G, Le Foll B. The effects of buspirone on occupancy of dopamine receptors and the rat gambling task. Psychopharmacology (Berl). 2017 Nov;234(22):3309-3320. doi: 10.1007/s00213-017-4715-5. Epub 2017 Aug 19. PubMed PMID: 28825117.

4: Santa Cruz MR, Hidalgo PC, Lee MS, Thomas CW, Holroyd S. Buspirone for the treatment of dementia with behavioral disturbance. Int Psychogeriatr. 2017 May;29(5):859-862. doi: 10.1017/S1041610216002441. Epub 2017 Jan 26. PubMed PMID: 28124634.

5: D'Amico JM, Butler AA, Héroux ME, Cotel F, Perrier JM, Butler JE, Gandevia SC, Taylor JL. Human motoneurone excitability is depressed by activation of serotonin 1A receptors with buspirone. J Physiol. 2017 Mar 1;595(5):1763-1773. doi: 10.1113/JP273200. Epub 2016 Dec 17. PubMed PMID: 27859267; PubMed Central PMCID: PMC5330870.

6: Chugani DC, Chugani HT, Wiznitzer M, Parikh S, Evans PA, Hansen RL, Nass R, Janisse JJ, Dixon-Thomas P, Behen M, Rothermel R, Parker JS, Kumar A, Muzik O, Edwards DJ, Hirtz D; Autism Center of Excellence Network. Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. J Pediatr. 2016 Mar;170:45-53.e1-4. doi: 10.1016/j.jpeds.2015.11.033. Epub 2015 Dec 30. PubMed PMID: 26746121.

7: Howland RH. Buspirone: Back to the Future. J Psychosoc Nurs Ment Health Serv. 2015 Nov;53(11):21-4. doi: 10.3928/02793695-20151022-01. Review. PubMed PMID: 26535760.

8: McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, DeVane CL, Norton J. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 1;156:29-37. doi: 10.1016/j.drugalcdep.2015.08.013. Epub 2015 Aug 25. PubMed PMID: 26386827; PubMed Central PMCID: PMC4633378.

9: Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson AA, Houle S, Meyer JH, Graff-Guerrero A, Boileau I. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. Neuropsychopharmacology. 2016 Jan;41(2):529-37. doi: 10.1038/npp.2015.177. Epub 2015 Jun 19. PubMed PMID: 26089182; PubMed Central PMCID: PMC5130128.